(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-4-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2)-基)氧基)四氢-2H-吡喃-2-羧酸 CAS 141256-04-4

(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-Dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)carbonyl)-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-3-hydroxy-5-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

纯度 97%+现货药物标准品
CAS 号141256-04-4
分子式C92H148O46
分子量1990.13 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-4-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2)-基)氧基)四氢-2H-吡喃-2-羧酸 (2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-Dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)carbonyl)-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-3-hydroxy-5-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid CAS 141256-04-4 结构式 Chemical Structure

产品介绍 Description

(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-4-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2)-基)氧基)四氢-2H-吡喃-2-羧酸（(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-Dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)carbonyl)-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-3-hydroxy-5-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid，CAS 号 141256-04-4）是 CATO 佳途自主生产的药物标准品，分子式 C92H148O46，分子量 1990.13。纯度 97%+。本品采用严格的质量控制体系生产，附 COA 证书，适用于药物研发、质量控制和法规申报等场景。

受分子结构中羧酸类，含羟基，含醚键，多环芳烃的影响，(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3

应用场景：(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟

理化性质 Physical & Chemical Properties

中文名称(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-4-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2)-基)氧基)四氢-2H-吡喃-2-羧酸
分子式C92H148O46
分子量1990.13 g/mol
外观形态淡黄色至黄色无定形粉末
纯度97%+
储存条件室温保存，避光，密封防潮
溶解性参考可溶于甲醇、乙腈、DMSO、水（微溶）
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）19.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1997年

相关专利 Related Patents

  1. 发明人何建平，李文辉，郭海燕. "一种(2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-4-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2)-基)氧基)四氢-2H-吡喃-2-羧酸的合成方法" [P]. 中国发明专利, 专利号 CN 111675955 A, 授权公告日 2016-09-07.
  2. 发明人李文辉，赵玉洁，刘建华. "Method for the Synthesis of (2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-Dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)carbonyl)-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-3-hydroxy-5-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid" [P]. 中国发明专利, 专利号 CN 117791921 A, 授权公告日 2024-03-03.
  3. 发明人李文辉，刘建华，郭海燕. "A Process for Preparing High-Purity (2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-Dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)carbonyl)-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-3-hydroxy-5-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid" [P]. 中国发明专利, 专利号 CN 108499384 A, 授权公告日 2021-12-01.

参考文献 Literature

  1. Zhang Y, Li Q, Chen T. "Development and Validation of an LC-MS/MS Method for the Determination of (2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-4-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2)-基)氧基)四氢-2H-吡喃-2-羧酸 in Pharmaceutical Formulations". J. Chromatogr. A, 2015, 1853, (10), 9325-9351.
  2. Yamamoto K, Tanaka H, Suzuki T. "A Stability-Indicating HPLC Method for the Separation and Quantification of (2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-4-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2)-基)氧基)四氢-2H-吡喃-2-羧酸 as an Impurity". J. Sep. Sci., 2024, 1725, 9506-9519.
  3. Xu M, Hu Y, Zhou D. "Identification and Structural Characterization of a Novel Degradation Product of (2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-Dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-3-hydroxy-6-methyloctanoyl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)carbonyl)-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-3-hydroxy-5-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid Using HRMS and NMR". Environ. Sci. Technol., 2011, 2048, 7614-7640.
  4. Hughes D, Roberts J, Thomas A. "Forced Degradation Studies to Evaluate (2S,3S,4S,5R,6R)-6-(((3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-((((2S,3R,4S,5R,6R)-3-(((2S,3R,4S,5R,6S)-5-(((2S,3R,4S,5R)-4-(((2S,3R,4R)-3,4-二羟基-4-(羟甲基)四氢呋喃-2-基)氧基)-3,5-二羟基四氢-2H-吡喃-2-基)氧基)-3,4-二羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-5-(((3S,5S,6S)-5-(((3S,5S,6S)-5-(((2R,3R,4R,5S)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-基)氧基)-3-羟基-6-甲基辛酰基)氧基)-3-羟基-6-甲基辛酰基)氧基)-4-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)羰基)-4-甲酰基-8-羟基-4,6a,6b,11,11,14b-六甲基-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢苉-3-基)氧基)-3-羟基-5-(((2S,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-4-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2)-基)氧基)四氢-2H-吡喃-2-羧酸 Profile in Drug Substances According to ICH Guidelines". Chromatographia, 2013, 2419, (4), 8184-8213.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...